Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: anti-viral small molecule therapeutics - Mateon Therapeutics

Drug Profile

Research programme: anti-viral small molecule therapeutics - Mateon Therapeutics

Latest Information Update: 12 Mar 2020

At a glance

  • Originator Mateon Therapeutics
  • Class Antivirals; Small molecules
  • Mechanism of Action Cathepsin K modulators; Cathepsin L modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - COVID 2019 infections; Viral infections

Highest Development Phases

  • Research COVID 2019 infections; Viral infections

Most Recent Events

  • 02 Mar 2020 Research programme: anti-viral small molecule therapeutics - Mateon Therapeutics is available for licensing as of 02 Mar 2020. https://www.oncotelic.com/
  • 02 Mar 2020 Early research in COVID-2019 infections in USA (unspecified route)
  • 02 Mar 2020 Early research in Viral infections in USA (unspecified route)

Development Overview

Introduction

Small molecule therapeutics targeting cathepsin L or cathepsin K is being developed by Mateon Therapeutics, for the treatment of coronavirus infectious disease (COVID-2019) as well as other viral diseases occurring due to severe acute respiratory syndrome (SARS) virus and Ebola virus; under a rapid antiviral response programme. The company will develop the therapeutics using its artificial intelligence platform; EdgePoint which processes machine learning models. Early research is underway in the US.

The small-molecule anti-viral programme which is being developed under Rapid Antiviral Response Program will be modeled after the ongoing EdgePoint AI development model at Mateon. After developing and establishing the technology, Mateon plans to form a separate company or sell the technology and the programme to a larger entity for further development.

Key Development Milestones

In March 2020, Mateon Therapeutics reported that it is evaluating the potential of its AI Vision technology to help monitor patients infected with the COVID-19 virus, or any other viruses [1] .

Drug Properties & Chemical Synopsis

  • Formulation unspecified
  • Class Antivirals, Small molecules
  • Target Cathepsin K; Cathepsin L
  • Mechanism of Action Cathepsin K modulators; Cathepsin L modulators
  • WHO ATC code

    J05A-X (Other antivirals)

  • EPhMRA code

    J5B (Antivirals, excluding anti-HIV products)

Development Status

Summary Table

Indication Qualifier Patient Segment Phase Countries Route / Formulation Developers Event Date
COVID 2019 infections - - Research USA unspecified / unspecified Mateon Therapeutics 02 Mar 2020
Viral infections - - Research USA unspecified / unspecified Mateon Therapeutics 02 Mar 2020

Commercial Information

Involved Organisations

Organisation Involvement Countries
Mateon Therapeutics Originator USA
Mateon Therapeutics Owner USA

Licensing Availability

Licensing Organisation Available Indication Available Phase Region Date
Mateon Therapeutics COVID 2019 infections, Viral infections Unspecified - 02 Mar 2020

Development History

Event Date Update Type Comment
02 Mar 2020 Licensing Status Research programme: anti-viral small molecule therapeutics - Mateon Therapeutics is available for licensing as of 02 Mar 2020. https://www.oncotelic.com/ Updated 12 Mar 2020
02 Mar 2020 Phase Change Early research in COVID-2019 infections in USA (unspecified route) [1] Updated 06 Mar 2020
02 Mar 2020 Phase Change Early research in Viral infections in USA (unspecified route) [1] Updated 06 Mar 2020

References

  1. Mateon Provides Update on its Rapid Antiviral Response Program Initially Targeting COVID-19.

    Media Release
Back to top